The Oncology Institute, Inc.

NasdaqCM:TOI

Market Cap

USD 335.48 M

Share Price

USD 3.65

Avg Daily Volume

1,814,421

Change (1 day)

-1.62%

Change (1 year)

Change (YTD)

409.71%

The Oncology Institute, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2025: -11.58%

The Oncology Institute, Inc. EBITDA Margin is -11.58% for the Trailing 12 Months (TTM) ending March 31, 2025, a -35.55% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • The Oncology Institute, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was -17.97%, a 35.92% change year over year.
  • The Oncology Institute, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was -13.22%, a -6.09% change year over year.
  • The Oncology Institute, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was -14.08%, a 517.62% change year over year.
  • The Oncology Institute, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was -2.28%.
Key Data
Date EBITDA Margin Net Income Margin EBT Margin Operating Income Margin